Related Experiment Video
Updated: Dec 1, 2025

Comprehensive Endovascular and Open Surgical Management of Cerebral Arteriovenous Malformations
Published on: October 20, 2017
Management of disseminated intravascular coagulation associated with aortic aneurysm and vascular malformations
Shinya Yamada1, Hidesaku Asakura2
1Department of Hematology, Kanazawa University Hospital, 13-1 Takaramachi, Kanazawa, Ishikawa, 920-8641, Japan. abacus3shinya@gmail.com.
Insights
Disseminated intravascular coagulation (DIC) associated with aortic aneurysms requires specific diagnostic markers beyond standard coagulation tests. Treatment focuses on the underlying condition, with pharmacotherapy options available for bleeding cases.
Area of Science:
- Vascular Medicine
- Hematology
- Coagulation Science
Background:
- Aortic aneurysms and vascular malformations can present with disseminated intravascular coagulation (DIC).
- Standard coagulation tests like PT and APTT are insufficient for diagnosing or ruling out DIC in these contexts.
Observation:
- Typical DIC lab findings include decreased platelets and fibrinogen, increased FDP and D-dimer.
- Elevated thrombin-antithrombin complex (TAT) and plasmin-α2 plasmin inhibitor (PIC) are observed.
- Reduced α2 plasmin inhibitor (α2PI) levels are noted, alongside potentially normal or shortened PT/APTT.
Findings:
- DIC diagnosis in these vascular conditions is complex and requires advanced markers.
- Thrombin-antithrombin complex (TAT), plasmin-α2 plasmin inhibitor (PIC), and α2 plasmin inhibitor (α2PI) are crucial indicators.
- Standard coagulation parameters (PT, APTT) have limited diagnostic utility.
Implications:
- Effective DIC management necessitates treating the underlying vascular disease.
- Pharmacotherapy, including anticoagulants and antifibrinolytics like tranexamic acid, is vital for bleeding patients.
- Monitoring TAT and PIC is essential, especially when α2PI is low or bleeding is severe.
Abstract:
Aortic aneurysms and vascular malformations are sometimes associated with disseminated intravascular coagulation (DIC). A typical blood coagulation test shows decrease in platelet count and fibrinogen, and increases in fibrin/fibrinogen degradation products (FDP) and D-dimer. The coagulation activation marker thrombin-antithrombin complex (TAT) and the fibrinolysis activation marker plasmin-α2 plasmin inhibitor (PIC) are significantly increased. α2 plasmin inhibitor (α2PI) is significantly reduced. Since no prolongation of prothrombin time (PT) is noticeable and activated partial thromboplastin time (APTT) is shortened in some cases, DIC cannot be diagnosed or ruled out by PT and APTT alone. The cornerstone of treatment for DIC is to treat the underlying disease. However, surgery is not possible in some cases. Follow-up may be appropriate in patients with abnormal results from coagulation tests and no bleeding. However, pharmacotherapy is often required in cases with bleeding. Unfractionated heparin, low molecular weight heparin, protease inhibitors, recombinant thrombomodulin, direct oral anticoagulants, and factor XIII preparations are effective. If PIC is significantly increased and α2PI is significantly decreased, or if the bleeding is severe, tranexamic acid is used as an antifibrinolytic therapy with anticoagulant therapy. In such cases, attention should be paid not only to TAT but also changes in PIC.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Aneurysm IV: Nursing Management
Aneurysm III: Interprofessional Care
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Aortic Regurgitation III: Medical Management
Venous Thrombosis IV: Nursing Management

